Nalm6-Fluc-GFP CDX Model

The Nalm6-Fluc-GFP cell line originates from human acute lymphoblastic leukemia (ALL), a rapidly progressing malignancy of the lymphoid lineage. The “Fluc-GFP” denotes modifications to express both firefly luciferase (Fluc) and green fluorescent protein (GFP), enabling real-time monitoring of tumor growth via bioluminescence imaging and direct visualization of cells using fluorescence. Nalm6-Fluc-GFP serves as a pivotal tool for detailed exploration of ALL pathogenesis, progression, and therapeutic responses. The cell line embodies molecular features and genetic anomalies emblematic of ALL, enhancing its role in preclinical investigations. The in vitro and in vivo behavior of Nalm6-Fluc-GFP, especially when paired with bioluminescence and fluorescence imaging, grants profound insights into the rapid growth kinetics, bone marrow involvement, and systemic spread of ALL. Researchers capitalize on the Nalm6-Fluc-GFP model to dissect molecular dynamics, interactions with the bone marrow microenvironment, and to evaluate and optimize therapeutic interventions for ALL.

Model Details

Cancer Location: Intravenous
Cancer Type: Acute Lymphoblastic Leukemia
Model Name: Nalm6-Fluc-GFP
Mouse Strain: CIEA NOG
Treatment Data Available: Chemotherapy (Lenalidomide)

HCC70 Growth curves

Nalm6-Fluc-GFP CDX Model

Growth of IV disseminated NALM6-fluc-GFP in CIEA NOG mice (n=5)

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.